Completed PHASE2 INTERVENTIONAL 1-arm NCT00305435

Safety Study of AMG 531 in Japanese Subjects With ITP

An Open Label Phase 2 Study Evaluating the Safety of Starting Dose of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Sponsor: Kyowa Kirin Co., Ltd.

Conditions Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Interventions Romiplostim (AMG-531)

Updated 8 times since 2017 Last updated: Jul 3, 2024 Started: Feb 28, 2006 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00305435, this PHASE2 trial focuses on Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) and remains completed. Sponsored by Kyowa Kirin Co., Ltd., it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Aug 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2024 — Aug 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Aug 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.